A man finishes 90 days at a residential program, gets on buprenorphine, does the meetings, and rebuilds a fragile life. Six months out, he sees the old neighborhood, smells the wrong thing on the wrong street, and his hand is already in his pocket. He was not weak. His reward center had been rewired during his years of use, and nothing in his treatment plan was designed to undo that wiring.
That is the gap a 2026 study from the University of Iowa, published January 21 in Neuropsychopharmacology, is starting to fill. John Wemmie, MD, PhD, and his team showed that a drug already in every hospital pharmacy, acetazolamide, used for decades to treat glaucoma, altitude sickness, and seizures, can reverse the synaptic changes opioids leave behind in the nucleus accumbens, the part of the brain that decides what is worth wanting.
The Wiring Problem No Current Medication Fixes
Methadone, buprenorphine, and naltrexone are good drugs. They keep people alive. They blunt withdrawal, they soften cravings, they buy time. But they all work the same way: they sit on the mu-opioid receptor (the exact receptor that morphine, fentanyl, and oxycodone bind to) and modulate it. That solves part of the problem. It does not solve the deeper one.
The deeper problem is this: long opioid use physically reshapes the synapses in the nucleus accumbens core. The connections between neurons become heavier on one side, the AMPA-to-NMDA receptor ratio shifts, and calcium-permeable AMPA receptors get inserted into spots they were not in before. These are not metaphors. They are measurable structural changes that biology textbooks would have called "learning" in a different context. The brain has learned the drug. That learning sits inside D1-expressing medium spiny neurons, and it does not unlearn just because a person stops using.
This is why the relapse statistics are so brutal. The National Institute on Drug Abuse estimates that 40 to 60 percent of people with substance use disorders relapse, and for opioids the rate runs higher when measured at one year. People are not failing willpower tests. They are walking around with a reward system that has been physically modified to seek the drug, and current medications do not address the modification.
What the Iowa Team Found
Wemmie's lab had already shown, in earlier work going back to 2023, that an enzyme called carbonic anhydrase 4 (CA4) is involved in the synaptic rearrangements that follow cocaine withdrawal. Inhibiting CA4 in mice reduced cocaine-seeking behavior and protected the nucleus accumbens from those structural shifts.
The new paper extends the work to opioids. The team gave mice oxycodone, let them go through withdrawal, and watched what happened in the NAcC. The synapses changed exactly as predicted: heavier AMPA-receptor signaling, more calcium-permeable receptors, the whole signature of relapse-prone wiring. Then they gave a single dose of acetazolamide. The synapses returned toward baseline. When the same mice were given a chance to self-administer oxycodone after a long abstinence, the acetazolamide group sought the drug less than the untreated group.
The mechanism is elegant. Acetazolamide blocks CA4, which sits in the synaptic cleft and modulates local pH. Block the enzyme and you boost the activity of acid-sensing ion channels (ASIC1A), a separate set of proteins that regulate how neurons respond to drug-induced changes. The result is a synapse that resists the rewiring opioids try to impose.
The authors are careful. This is animal work. The drug has not yet been tested in humans with opioid use disorder. But acetazolamide is already FDA-approved, the safety profile is well-characterized, and the path from "promising mouse data" to "first human trial" is shorter for a repurposed drug than for a novel molecule. As Wemmie put it in the press release, "AZD is already approved for human use and has a good safety profile, which raises the exciting possibility that it might be readily repurposed."
Why This Reframes the Whole Conversation About Relapse
For thirty years I have watched people in recovery be told, in subtle and not-subtle ways, that staying clean is a matter of motivation. Work the steps harder. Want it more. Find the meeting. None of that is wrong; community and accountability matter. But it loaded the entire failure of treatment onto the patient's character, when most of the failure was sitting inside the synapses.
A drug that resets the synapses changes the framing. It tells the patient and the family what is actually true: this is not about willpower. It never was. Relapse risk has a biological substrate, and biological substrates respond to biological treatment. That message, delivered alongside the clinical work, is one of the most therapeutic things a clinician can hand someone who has been told for years that they just need to try harder.
This is the same principle that drives our Rescue From Rehab approach at The Neurogenesis Project. Conventional rehab stops at abstinence and behavioral support. We go further, treating addiction the way we treat any other chronic brain disease: with the same precision diagnostics, the same nutritional and metabolic correction, and the same readiness to use emerging pharmacology when the evidence supports it. The Iowa work is exactly the kind of mechanistic finding that, in a few years, may sit alongside buprenorphine and naltrexone as a standard tool. We are watching it closely.
What You Should Do With This Information
If you or someone you love is in early recovery from opioid use disorder, do not stop your current medications based on a single mouse study. That would be the wrong takeaway. Acetazolamide is not yet a treatment for OUD, and the clinical trials that would establish dose, duration, and safety in this population have not been run.
What this study does justify is a different conversation with your treatment team. Ask whether the plan you are on addresses the synaptic rewiring of long opioid use, or only the receptor-level withdrawal. Ask what is being done to support the actual recovery of the reward system: the nutritional cofactors for dopamine synthesis, the sleep and exercise inputs that drive neuroplasticity, the management of stress hormones that prime relapse. The brain that learned addiction can also learn its way back, but it needs the right inputs to do it. Targeted nutritional support is one piece of that, which is why we developed the formulations at Action Potential Supplements to fill the metabolic gaps that standard recovery plans miss.
The Iowa team has done something important. They have shown, in clean experimental data, that the wiring problem at the core of relapse is not permanent. It is treatable. That is a message of dignity and of hope, and it belongs to everyone in recovery.